Compare FSK & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | CPRX |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | 2008 | 2006 |
| Metric | FSK | CPRX |
|---|---|---|
| Price | $10.35 | $31.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $13.19 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 18.82% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | N/A | $10.51 |
| P/E Ratio | ★ N/A | $62.84 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $9.72 | $19.05 |
| 52 Week High | $22.68 | $32.56 |
| Indicator | FSK | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 72.18 |
| Support Level | $9.85 | $31.25 |
| Resistance Level | $10.56 | $32.56 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 30.61 | 81.31 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.